Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

dermata therapeutics inc - DRMA

DRMA

Close Chg Chg %
0.86 -0.08 -9.61%

Closed Market

0.78

-0.08 (9.61%)

Volume: 124.39K

Last Updated:

Oct 23, 2026, 4:00 PM EDT

Trade Now

Company Overview: dermata therapeutics inc - DRMA

DRMA Key Data

Open

$0.83

 Day Range

0.77 - 0.85

52 Week Range

0.60 - 4.66

 Market Cap

$3.96M

Shares Outstanding

4.96M

 Public Float

2.86M

Beta

0.66

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.39

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

7.97M

  

DRMA Performance

1 Week
 
 -9.19%
 
1 Month
 
 -31.49%
 
3 Months
 
 -40.83%
 
1 Year
 
 -80.51%
 
5 Years
 
 -99.99%
 

DRMA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About dermata therapeutics inc - DRMA

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.

DRMA At a Glance

Dermata Therapeutics, Inc.
3525 Del Mar Heights Road
San Diego, California 92130
Phone 1-858-800-2543 Revenue 0.00
Industry Household/Personal Care Net Income -7,558,557.00
Sector Consumer Non-Durables Employees 9
Fiscal Year-end 12 / 2026
View SEC Filings

DRMA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 0.992
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.691
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

DRMA Efficiency

Revenue/Employee N/A
Income Per Employee -839,839.667
Receivables Turnover N/A
Total Asset Turnover N/A

DRMA Liquidity

Current Ratio 4.794
Quick Ratio 4.794
Cash Ratio 4.585

DRMA Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -132.633
Return on Equity -194.196
Return on Total Capital -121.454
Return on Invested Capital -194.196

DRMA Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Dermata Therapeutics Inc - DRMA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
- - - -
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - - -
-
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
- - - -
-
Gross Income
- - - -
-
Gross Income Growth
- - - -
-
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
9.67M 8.04M 12.51M 7.77M
Research & Development
5.65M 4.07M 8.20M 2.93M
Other SG&A
4.02M 3.97M 4.31M 4.84M
SGA Growth
+23.13% -16.88% +55.60% -37.88%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(9.67M) (8.04M) (12.51M) (7.77M)
Non Operating Income/Expense
63.57K 247.22K 225.78K 215.04K
Non-Operating Interest Income
63.57K 247.22K 225.78K 215.04K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -100.00%
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(9.61M) (7.79M) (12.29M) (7.56M)
Pretax Income Growth
-21.62% +18.90% -57.64% +38.49%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(9.61M) (7.79M) (12.29M) (7.56M)
Minority Interest Expense
- - - -
-
Net Income
(9.61M) (7.79M) (12.29M) (7.56M)
Net Income Growth
-21.62% +18.90% -57.64% +38.49%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(9.61M) (7.79M) (12.29M) (7.56M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(9.61M) (7.79M) (12.29M) (7.56M)
EPS (Basic)
-2087.304 -399.81 -80.3222 -8.1609
EPS (Basic) Growth
+30.78% +80.85% +79.91% +89.84%
Basic Shares Outstanding
4.60K 19.50K 152.98K 926.19K
EPS (Diluted)
-2087.304 -399.81 -80.3222 -8.1609
EPS (Diluted) Growth
+30.78% +80.85% +79.91% +89.84%
Diluted Shares Outstanding
4.60K 19.50K 152.98K 926.19K
EBITDA
(9.67M) (8.04M) (12.51M) (7.77M)
EBITDA Growth
-23.13% +16.88% -55.60% +37.88%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 4.00
Number of Ratings 1 Current Quarters Estimate -0.46
FY Report Date 12 / 2026 Current Year's Estimate -2.17
Last Quarter’s Earnings -0.55 Median PE on CY Estimate N/A
Year Ago Earnings -8.16 Next Fiscal Year Estimate -1.43
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate -0.46 -0.42 -2.17 -1.43
High Estimates -0.46 -0.42 -2.17 -1.43
Low Estimate -0.46 -0.42 -2.17 -1.43
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Dermata Therapeutics Inc - DRMA

Date Name Shares Transaction Value
Oct 15, 2026 Gerald T. Proehl PRESIDENT, CHAIRMAN, CEO; Director 292,631 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 15, 2026 Gerald T. Proehl PRESIDENT, CHAIRMAN, CEO; Director 170,068 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 15, 2026 Gerald T. Proehl PRESIDENT, CHAIRMAN, CEO; Director 170,068 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 15, 2026 Proehl Investment Ventures LLC PRESIDENT, CHAIRMAN, CEO; Director 1,360,544 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 15, 2026 Proehl Investment Ventures LLC PRESIDENT, CHAIRMAN, CEO; Director 1,360,544 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 15, 2026 Proehl Investment Ventures LLC PRESIDENT, CHAIRMAN, CEO; Director 1,360,544 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Maria Bedoya-Toro Munera SVP, Regulatory Affairs 9,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Mary M. Fisher Director 2,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Steven J. Mento Director 2,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Brittany K. Bradrick Director 2,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Kyri K. van Hoose SVP, CFO 18,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Dermata Therapeutics Inc in the News